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Abstract
Orbifloxacin is a fluoroquinolone drug used widely in companion animal medicine. In this study, we firstly
determined post-antibiotic effects (PAEs) and post-antibiotic sub-minimum inhibitory concentrations (MIC) effects
(PA-SMEs) of orbifloxacin for two strains each of Escherichia coli and Pseudomonas aeruginosa from dogs, and these
parameters were compared with those of enrofloxacin. At twice the MIC, the PAEs of orbifloxacin ranged from
-0.28-0.93 h (mean, 0.29 h) for E. coli and -0.18-1.18 h (mean, 0.37 h) for P. aeruginosa. These parameters were not
significantly different for E. coli and shorter for P. aeruginosa, compared to enrofloxacin (P < 0.05). Continued
exposure to 0.1, 0.2, and 0.3 the MIC of orbifloxacin resulted in average PA-SMEs of 0.55, 1.11, and 2.03 h,
respectively, for E. coli, and 1.04, 1.40, and 2.47 h, respectively, for P. aeruginosa. These PA-SMEs, which had no
significant differences with those of enrofloxacin, were significantly longer than the corresponding PAEs (P < 0.05).
These results suggest that the PA-SME of orbifloxacin for E. coli and P. aeruginosa can be meaningfully prolonged
by increase of sub-MICs.
Findings
Orbifloxacin is a fluoroquinolone developed for use in
companion animal medicine. This antimicrobial agent
exhibits bactericidal activity against numerous gram-
negative and gram-positive bacteria. In canine practice,
orbifloxacin is indicated for the treatment of various
infections, including urinary, skin, and otitis infections,
and is available in many countries including Japan.
Pharmacodynamic variables such as the post-antibiotic
effect (PAE) and post-antibiotic sub-minimum inhibitory
concentration effect (PA-SME) have increasingly become
the focus of investigations designed to determine opti-
mal dosage regimens for antimicrobial agents. The PAE
is defined as the length of time that bacterial growth is
suppressed following brief exposure to an antibiotic [1].
PAE has been investigated for several veterinary fluoro-
quinolones, such as enrofloxacin, marbofloxacin, and
difloxacin [2-5], but not for orbifloxacin. On the other
hand, PA-SME is defined as the time interval that
includes the PAE plus the additional time during which
growth is suppressed by sub-MICs, and has not been
investigated for all veterinary fluoroquinolones, includ-
ing orbifloxacin. In this study, we examined the in vitro
PAEs and PA-SMEs of orbifloxacin against Escherichia
coli and Pseudomonas aeruginosa, which are representa-
tive gram-negative pathogens responsible for urinary
and skin infections, respectively, in dogs, and these
values were compared with those for enrofloxacin.
Two strains each of E. coli (strains 09-207 and 09-225)
and P. aeruginosa (strains 33 and 72) were used in this
study. These organisms were isolated from canine urine
(E. coli)a n ds k i n( P. aeruginosa), and identified by gram
stain, catalase, and oxidase tests and Api 20E kit (Bio
Merieux, France). MICs of orbifloxacin and enrofloxacin
were determined by the agar dilution method according
to the guidelines of the Clinical and Laboratory Standards
Institute [6]. E. coli ATCC 25922 and P. aeruginosa
ATCC 27853 were used as quality control strains.
The PAE and PA-SME of orbifloxacin were examined in
comparison with enrofloxacin, and were performed in
accordance with procedures described previously [7]. Each
strain was grown in the logarithmic growth phase to a
concentration of approximately 5 × 10
6 colony-forming
u n i t s( C F U ) / m La n dw a sp r e p a r e df o ru s ei nP A E
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enrofloxacin at twice the MIC reduced the starting inocu-
lum by approximately 1-2 log10 units. Growth controls
with inoculum but no antibiotic were included for each
experiment. Tubes were placed in a shaking water bath at
35°C for 1 h. Following exposure to fluoroquinolones, bac-
teria were removed from the fluoroquinolones by pelleting
the cells by centrifugation at appropriate conditions. The
bacteria were resuspended in fresh, drug-free cation-
adjusted Mueller-Hinton broth (CAMHB), once again pel-
leted by centrifugation, and resuspended again in fresh,
drug-free CAMHB. Control organisms were not exposed
to either fluoroquinolone but were treated similarly.
Following drug removal, the fluoroquinolone-exposed and
control cultures were placed in fresh media and incubated
in a water bath at 35°C with agitation (100 rpm). Viability
counts were determined before exposure, immediately
after centrifugation (0 h), and then hourly for 5 h by plate
counting. A test of final colony counts was performed
at 24 h to allow for the sufficient growth of all samples.
The PAE was defined according to the formula: PAE (in
hours) = T-C,w h e r eT is the time required for viability
counts of an antibiotic-exposed culture to increase by 1
log unit above counts taken immediately after dilution and
C is the corresponding time for the growth control, as pre-
viously described [1].
In cultures designated for PA-SME, the PA-phase E.
coli or P. aeruginosa organisms were exposed to differ-
ent sub-MICs (0.1, 0.2, and 0.3 times the MIC) of orbi-
floxacin and enrofloxacin. One sample of PA-phase
bacteria to which no drug was added served as the con-
trol. All samples and controls were incubated in a water
bath at 35°C with agitation (100 rpm) and the growth of
all cultures was monitored by determining viable cell
counts, as described above. The PA-SME was calculated
using the equation: PA-SME (in hours) = TPA-C,w h e r e
TPA is the time required for sub-MIC-treated PA-phase
o r g a n i s m st og r o wt o1l o gu n i ta n dC is the time
required for unexposed organisms to grow to 1 log unit,
as previously described [1]. The PAE and PA-SME were
measured in three independent experiments. The Stu-
dent’s t test was used to determine the significant differ-
ences (P < 0.05) between the two groups. For each
experiment, viability counts (log CFU/mL) were plotted
against time and expressed as the means of results from
three separate assays. The fluctuations of bacterial num-
bers during experiments are shown in Figures 1, 2, 3, 4,
and MICs, PAEs, and PA-SMEs are summarized in
Table 1.
In this study, the average PAE of orbifloxacin for E.
coli was not significantly different from that of enroflox-
acin (0.29 h vs. 0.32 h, P = 0.84), whereas the average
PAE of orbifloxacin for P. aeruginosa was significantly
shorter than that of enrofloxacin (0.37 h vs. 0.87 h, P =
0.022). In previous studies, van den Hoven et al. [3]
reported that difloxacin had PAEs of 0.5 h for E. coli
and -0.4 h for P. aeruginosa.S p r e n get al. [2] reported
PAEs for marbofloxacin that ranged from 0.6 to 0.9 h
for E. coli. These PAEs were induced by the exposure of
t h ed r u ga tt w i c et h eM I Cf o r1h ,w h i c hi st h es a m e
Figure 1 PAE and PA-SME of orbifloxacin and enrofloxacin for E. coli 09-207. Pre: The time of beginning exposure to the fluoroquinolone
at twice the MIC. Post: The time of discontinuing exposure to the fluoroquinolone at twice the MIC.
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likely to have average PAEs for E. coli and P. aeruginosa
among veterinary fluoroquinolone drugs.
The PA-SMEs have been studied extensively in most
antibiotics with bacterial species in human medicine [1]
but not in veterinary medicine. In this study, we first
determined PA-SMEs of two veterinary fluoroquino-
lones, orbifloxacin and enrofloxacin. Following contin-
ued exposure to orbifloxacin at 0.1, 0.2, and 0.3 times
the MIC, the average PA-SMEs were observed at 0.55,
1.11, and 2.03 h, respectively, for E. coli, and 1.04, 1.40,
and 2.47 h, respectively, for P. aeruginosa. On the other
hand, the PA-SMEs of enrofloxacin at each concentra-
tion were 0.58, 0.87, and 1.38 h, respectively, for E. coli
and 1.22, 1.31, and 1.94 h, respectively, for P. aerugi-
nosa. There were no significant differences in values of
PA-SMEs between orbifloxacin and enrofloxacin (P ≥
0.17). The PA-SMEs of both drugs were significantly
Figure 2 PAE and PA-SME of orbifloxacin and enrofloxacin for E. coli 09-225. Pre: The time of beginning exposure to the fluoroquinolone
at twice the MIC. Post: The time of discontinuing exposure to the fluoroquinolone at twice the MIC.
Figure 3 PAE and PA-SME of orbifloxacin and enrofloxacin for P. aeruginosa 72. Pre: The time of beginning exposure to the
fluoroquinolone at twice the MIC. Post: The time of discontinuing exposure to the fluoroquinolone at twice the MIC.
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may suggest that the PA-SME of orbifloxacin, as well as
enrofloxacin, for E. coli and P. aeruginosa can be pro-
longed by increased sub-MICs.
The relationship between MIC and pharmacodynamic
parameters, including PAE and PA-SME, is not entirely
understood. This study showed that the strains with
higher MICs of orbifloxacin and enrofloxacin (i.e. E. coli
09-225 and P. aeruginosa 33) consistently showed shorter
PAE and PA-SME, compared with those with lower
MICs (i.e. E. coli 09-207 and P. aeruginosa 72), respec-
tively. Notably, there were significant differences in the
PA-SMEs of orbifloxacin at 0.2 and 0.3 times the MIC
between the two E. coli strains (P ≤ 0.027). These results
suggest that MICs can affect the periods of PAE and PA-
SME in bacteria. However, Licata et al. [7] reported that
the two strains of Staphylococcus aureus,w i t ht h es a m e
MICs, showed different PAEs and PA-SMEs. Therefore,
t h ee f f e c to fM I C so nP A E sa n dP A - S M E si nb a c t e r i a
requires further investigation.
In conclusion, our study showed that orbifloxacin has
meaningful PAEs and PA-SMEs for E. coli and P. aeru-
ginosa isolates from dogs. The exposure concentrations
of orbifloxacin to induce PAE and PA-SME in this study
are achievable at each infection site (i.e., urine and skin)
by usual therapeutic doses [8,9]. For these organisms,
Table 1 PAEs and PA-SMEs of orbifloxacin and enrofloxacin for canine E.coli and P. aeruginosa isolates
Organism (origin) Antibiotic MIC (μg/ml) PAE (h)
a, b PA SME (h)
b
0.1 the MIC 0.2 the MIC 0.3 the MIC
E. coli 09-207 Orbifloxacin 0.125 0.53 (0.12-0.93) 0.80 (0.54-1.27) 1.61 (1.31-2.00) 3.04 (2.68-3.70)
Enrofloxacin 0.031 0.52 (-0.12-0.99) 0.76 (0.10-1.50) 1.15 (0.45-2.04) 1.93 (1.07-2.72)
E. coli 09-225 Orbifloxacin 2 0.05 (-0.28-0.27) 0.29 (0.09-0.51) 0.61 (0.20-0.84) 1.02 (0.46-1.31)
Enrofloxacin 0.5 0.13 (-0.11-0.54) 0.40 (-0.08-0.85) 0.60 (0.01-1.40) 0.84 (0.12-1.34)
E. coli (mean) Orbifloxacin - 0.29 0.55 1.11 2.03
Enrofloxacin - 0.32 0.58 0.87 1.38
P. aeruginosa 72 Orbifloxacin 2 0.62 (0.25-1.18) 1.19 (0.59-1.81) 1.65 (0.86-2.23) 3.34 (1.34-6.14)
Enrofloxacin 0.5 1.04 (0.79-1.39) 1.37 (1.08-1.81) 1.42 (1.25-1.66) 2.15 (1.37-2.71)
P. aeruginosa 33 Orbifloxacin 4 0.13 (-0.18-0.50) 0.88 (0.55-1.78) 1.14 (0.54-1.90) 1.60 (0.64-2.27)
Enrofloxacin 1 0.71 (0.05-1.53) 1.06 (0.31-1.95) 1.20 (0.43-2.14) 1.74 (1.07-2.74)
P. aeruginosa (mean) Orbifloxacin - 0.37 1.04 1.40 2.47
Enrofloxacin - 0.87 1.22 1.31 1.94
aOrganisms exposed to two times the MIC.
bAverages of three individual experiments; ranges in parentheses.
Figure 4 PAE and PA-SME of orbifloxacin and enrofloxacin for P. aeruginosa 33. Pre: The time of beginning exposure to the
fluoroquinolone at twice the MIC. Post: The time of discontinuing exposure to the fluoroquinolone at twice the MIC.
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potency (e.g. bactericidal effect [10] and postantibiotic
leukocyte enhancement [11]) remain to be clarified. To
additionally validate regimen of veterinary fluoroquino-
lones including orbifloxacin, further studies would be
needed.
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